These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34762364)

  • 1. Possible mechanisms for treatment heterogeneity in clinical trials of adjunctive N-acetylcysteine for bipolar depression.
    Brown A; Glue P
    Bipolar Disord; 2022 Mar; 24(2):213. PubMed ID: 34762364
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials.
    Pittas S; Theodoridis X; Haidich AB; Bozikas PV; Papazisis G
    Psychopharmacology (Berl); 2021 Jul; 238(7):1729-1736. PubMed ID: 33641060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and meta-analysis of randomized controlled trials.
    Nery FG; Li W; DelBello MP; Welge JA
    Bipolar Disord; 2021 Nov; 23(7):707-714. PubMed ID: 33354859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials.
    Kishi T; Miyake N; Okuya M; Sakuma K; Iwata N
    Psychopharmacology (Berl); 2020 Nov; 237(11):3481-3487. PubMed ID: 32767039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study.
    Ellegaard PK; Licht RW; Nielsen RE; Dean OM; Berk M; Poulsen HE; Mohebbi M; Nielsen CT
    J Affect Disord; 2019 Feb; 245():1043-1051. PubMed ID: 30699846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.
    Berk M; Turner A; Malhi GS; Ng CH; Cotton SM; Dodd S; Samuni Y; Tanious M; McAulay C; Dowling N; Sarris J; Owen L; Waterdrinker A; Smith D; Dean OM
    BMC Med; 2019 Jan; 17(1):18. PubMed ID: 30678686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive
    Ashton MM; Dean OM; Marx W; Mohebbi M; Berk M; Malhi GS; Ng CH; Cotton SM; Dodd S; Sarris J; Hopwood M; Faye-Chauhan K; Kim Y; Dash SR; Jacka FN; Shivappa N; Hebert JR; Turner A
    Aust N Z J Psychiatry; 2020 Feb; 54(2):159-172. PubMed ID: 31661974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.
    Berk M; Copolov DL; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Bush AI
    Biol Psychiatry; 2008 Sep; 64(6):468-75. PubMed ID: 18534556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
    Rajagopalan K; Bacci ED; Ng-Mak D; Wyrwich K; Pikalov A; Loebel A
    BMC Psychiatry; 2016 May; 16():157. PubMed ID: 27215976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.
    Berk M; Dean O; Cotton SM; Gama CS; Kapczinski F; Fernandes BS; Kohlmann K; Jeavons S; Hewitt K; Allwang C; Cobb H; Bush AI; Schapkaitz I; Dodd S; Malhi GS
    J Affect Disord; 2011 Dec; 135(1-3):389-94. PubMed ID: 21719110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial.
    Bortolasci CC; Turner A; Mohebbi M; Liu ZS; Ashton M; Gray L; Marx W; Walker AJ; Kowalski GM; Jacka F; Berk M; Dean OM; Walder K
    J Psychiatr Res; 2021 Oct; 142():376-383. PubMed ID: 34438354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression.
    Bauer IE; Green C; Colpo GD; Teixeira AL; Selvaraj S; Durkin K; Zunta-Soares GB; Soares JC
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 and total antioxidant capacity levels following
    Bortolasci CC; Voigt C; Turner A; Mohebbi M; Gray L; Dodd S; Walder K; Berk M; Cotton SM; Malhi GS; Ng CH; Dowling N; Sarris J; Dean OM
    Acta Neuropsychiatr; 2020 Dec; 32(6):313-320. PubMed ID: 32600481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial.
    Magalhães PV; Dean OM; Bush AI; Copolov DL; Malhi GS; Kohlmann K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Berk M
    J Affect Disord; 2011 Mar; 129(1-3):317-20. PubMed ID: 20800897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine for major depressive episodes in bipolar disorder.
    Magalhães PV; Dean OM; Bush AI; Copolov DL; Malhi GS; Kohlmann K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Berk M
    Braz J Psychiatry; 2011 Dec; 33(4):374-8. PubMed ID: 22189927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.
    Dean OM; Turner A; Malhi GS; Ng C; Cotton SM; Dodd S; Sarris J; Samuni Y; Tanious M; Dowling N; Waterdrinker A; Smith D; Berk M
    Braz J Psychiatry; 2015; 37(1):3-12. PubMed ID: 25295681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of N-acetyl cysteine on cognitive function in bipolar disorder.
    Dean OM; Bush AI; Copolov DL; Kohlmann K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Berk M
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):514-7. PubMed ID: 23066769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial.
    Ashton MM; Mohebbi M; Turner A; Marx W; Berk M; Malhi GS; Ng CH; Cotton SM; Dodd S; Sarris J; Hopwood M; Stubbs B; Dean OM
    Can J Psychiatry; 2020 May; 65(5):306-318. PubMed ID: 31775518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Olanzapine in the treatment of bipolar disorder].
    Krüger S
    Psychiatr Prax; 2006 Mar; 33 Suppl 1():S18-26. PubMed ID: 16511727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression.
    Toniolo RA; Silva M; Fernandes FBF; Amaral JAMS; Dias RDS; Lafer B
    J Neural Transm (Vienna); 2018 Feb; 125(2):247-257. PubMed ID: 29177955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.